Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 WuXi Biologics Completes EMA GMP Inspection | Contract Pharma

What are you searching for?

Sign in
Breaking News

WuXi Biologics Completes EMA GMP Inspection

Becomes the first biologics company in China to do so

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The European Medicines Agency (EMA) has completed the Pre-Approval Inspection (PAI) of Wuxi Biologics’ cGMP drug substance (DS) and drug product (DP) manufacturing facilities for the production of TaiMed Biologics’ Trogarzo with no critical findings. WuXi Biologics will submit responses to the EMA inspection report in March 2019 and expects to obtain GMP certification for its facilities in May 2019.
 
According to the company, this is the first inspection of its kind in China. Upon completion of this inspection, WuXi Biologics will become the first cGMP biologics DS facility, the first cGMP biologics DP facility and the first cGMP cell banking facility in China to be approved by the EMA for commercial manufacturing. The DS and DP facilities also made headlines in March 2018 for being the first in China to pass the U.S. FDA inspection enabling the facilities to supply biologics globally.
 
“We are excited about this inspection result, which manifests our world-class quality system that meets global quality standards. We are thankful to our global clients who trust WuXi Biologics and to our staffs who tirelessly strive for excellence in quality,” said Chris Chen, chief executive officer, WuXi Biologics. “WuXi Biologics is committed to the continued expansion of our global manufacturing footprint, of the highest quality, as underlined by the recent FDA and EMA inspections. This result further allows us to expedite our ‘Follow-the-Molecule’ strategy for our clients, and continue to accelerate and transform how biologics are discovered, developed and manufactured. More high quality biologics will surely benefit patients globally.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics